LX1001

BIOLOGICAL2 trials

Sponsors

Lexeo Therapeutics

Conditions

Alzheimer DiseaseEarly Onset Alzheimer Disease

Phase 1

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

CompletedNCT03634007

Lexeo TherapeuticsAlzheimer Disease, Early Onset Alzheimer Disease

Start: 2019-11-06End: 2024-11-07Updated: 2025-10-17

Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease

Active, not recruitingNCT05400330

Lexeo TherapeuticsAlzheimer Disease

Start: 2023-05-08End: 2028-11-30Updated: 2025-07-01

Related Papers

Topline results from Phase 1/2 AAV gene therapy (LX1001) in APOE4/4 homozygotes with Alzheimer’s disease

Alzheimer s & Dementia2025-12-01

Assessment of Residual Full-Length SV40 Large T Antigen in Clinical-Grade Adeno-Associated Virus Vectors Produced in 293T Cells

Human Gene Therapy2023-05-126 citations